P. B. Grabar

Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach

C. Rodríguez-Antona, J. Jazbec, V. Dolžan, 2017, Radiology and oncology.

Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis

A. Mrhar, B. Rozman, D. Logar, 2009 .

Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway

D. Logar, V. Dolžan, P. B. Grabar, 2010, Annals of the rheumatic diseases.

Investigation of the Influence of CYP1A2 and CYP2C19 Genetic Polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) Pharmacokinetics in Leflunomide-Treated Patients with Rheumatoid Arthritis

A. Mrhar, M. Tomšič, Lucija Peterlin Mašič, 2009, Drug Metabolism and Disposition.

Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis

S. Praprotnik, B. Rozman, D. Logar, 2009, Annals of the rheumatic diseases.